AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
April 02, 2024 07:30 ET
|
AIM ImmunoTech Inc.
Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30 AM...
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
March 26, 2024 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 22, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
AIM ImmunoTech Announces Launch of CEO Corner Platform
March 07, 2024 08:45 ET
|
AIM ImmunoTech Inc.
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
February 29, 2024 08:45 ET
|
AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy
February 15, 2024 09:39 ET
|
Aviv Clinics
ORLANDO, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Today, Aviv Clinics reveals results from the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University from...
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
February 08, 2024 08:50 ET
|
AIM ImmunoTech Inc.
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
electroCore Expands Intellectual Property Portfolio
February 06, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...